LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending two key conferences during the month of June in San Francisco. The first conference, BIO International Convention (BIO), held June 6-9th at the Moscone Center, draws over 15,000 biotechnology and pharma leaders together for a week of intensive networking and partnering to discover new opportunities in drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy, a focus critical to HemaCare. The International Society of Stem Cell Research (ISSCR) will be conducted June 22nd-25th, also at the Moscone Center. This meeting is the premiere gathering of research and development scientists, to share and collaborate on advancements in stem cell therapies and treatments. HemaCare is actively expanding its capabilities in support of stem cell research based on increased demand for our portfolio of stem-cell enriched, mobilized peripheral blood and bone marrow-derived primary cells.
“We are attending BIO to expand our opportunities to support novel approaches to research and development of cell therapies, which requires our portfolio of human hematopoietic primary cells. The attendees of BIO are making critical advances every day that give patients with chronic illnesses hope for life-saving treatments. HemaCare is supporting ISSCR to participate alongside opinion-leading researchers as they share their accomplishments as well as their needs to continue stem-cell based work. HemaCare’s portfolio of human stem cells derived from hematopoietic tissues is a necessary component to develop and implement these innovative treatments and cures for diseases where stem cell advancements promise to undo previously irreversible damage,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We understand the critical need researchers have for our products and specialized capabilities and will continue to support these important meetings as we dedicate our business to aid in the pursuit of these treatments.”
View our product story at www.hemacare.com or visit us in San Francisco at BIO at booth 5881 or at ISSCR at booth 1808 .
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. HemaCare’s expertise extends to serving biopharmaceutical firms with autologous and allogeneic collections used for Cell Therapy research, process development, and clinical trials. For more information please visit www.hemacare.com.